Hengrui Medicine gains approval for clinical trials

Jiangsu Hengrui Medicine [SSE:600276] announced that its subsidiaries, Suzhou Shengdiya Biomedical and Shanghai Shengdi Pharmaceutical, have received approval from the National Medical Products Administration for clinical trials of SHR-8068 injection and Aidelbeli Monoclonal Antibody injection. The trials will commence soon. Specifically, SHR-8068 will be tested in combination with Aidelbeli and platinum-containing chemotherapy as a first-line treatment for PD-L1 negative advanced or metastatic non-small cell lung cancer.